AstraZeneca has announced that the FDA has approved Tagrisso for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Www.pharmatimes.com/intcr
Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement of its single-cancer and tailored multi-cancer early detection tests developed on its multiomics platform.
Samedan ltd presents International Clinical Trials (ICT)
Welcome to the March 2024 issue of Pharmafocus!
GSK has announced that the FDA has granted fast track designation for bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis b.
Considering the increase in measles cases and the benefits of vaccination
Pharmarole.com
Johnson & Johnson has announced that the FDA has granted breakthrough therapy designation for nipocalimab for the treatment of alloimmunised pregnant individuals at high risk of severe haemolytic disease of the foetus and newborn.
Argenx has announced that the FDA has accepted a supplemental biologics license application (sBLA) for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for priority review.
Domainex has announced that it has opened a new biology centre of excellence at the Unity Campus at Pampisford, Cambridge, UK, in order to further support collaborations with pharmaceutical and biotechnology companies, patient foundations and academic institutions.
Roche has announced data from stage 1 of the NIH-sponsored phase 3 outmatch trial, which assessed the safety and efficacy of Xolair (omalizumab) in patients allergic to peanuts and at least two other common foods.